Dynamic prediction: A challenge for biostatisticians, but greatly needed by patients, physicians and the public

Prognosis is usually expressed in terms of the probability that a patient will or will not have experienced an event of interest t years after diagnosis of a disease. This quantity, however, is of little informative value for a patient who is still event-free after a number of years. Such a patient would be much more interested in the conditional probability of being event-free in the upcoming t years, given that he/she did not experience the event in the s years after diagnosis, called "conditional survival." It is the simplest form of a dynamic prediction and can be dealt with using straightforward extensions of standard time-to-event analyses in clinical cohort studies. For a healthy individual, a related problem with further complications is the so-called "age-conditional probability of developing cancer" in the next t years. Here, the competing risk of dying from other diseases has to be taken into account. For both situations, the hazard function provides the central dynamic concept, which can be further extended in a natural way to build dynamic prediction models that incorporate both baseline and time-dependent characteristics. Such models are able to exploit the most current information accumulating over time in order to accurately predict the further course or development of a disease. In this article, the biostatistical challenges as well as the relevance and importance of dynamic prediction are illustrated using studies of multiple myeloma, a hematologic malignancy with a formerly rather poor prognosis which has improved over the last few years.

[1]  Martin Schumacher,et al.  Multi-state model for studying an intermediate event using time-dependent covariates: application to breast cancer , 2013, BMC Medical Research Methodology.

[2]  Thomas A Gerds,et al.  Comparing predictions among competing risks models with time‐dependent covariates , 2013, Statistics in medicine.

[3]  Willi Sauerbrei,et al.  Comparison of procedures to assess non‐linear and time‐varying effects in multivariable models for survival data , 2011, Biometrical journal. Biometrische Zeitschrift.

[4]  Martin Schumacher,et al.  Measures of prediction error for survival data with longitudinal covariates , 2011, Biometrical journal. Biometrische Zeitschrift.

[5]  Irwin Nazareth,et al.  Landmark Models for Optimizing the Use of Repeated Measurements of Risk Factors in Electronic Health Records to Predict Future Disease Risk , 2018, American journal of epidemiology.

[6]  Nathan Mantel,et al.  Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .

[7]  N. Weiss,et al.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. , 2013, Journal of the National Cancer Institute.

[8]  H. Goldschmidt,et al.  Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response , 2017, Cancer medicine.

[9]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[10]  W. Sauerbrei,et al.  Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Dimitris Rizopoulos,et al.  Joint Models for Longitudinal and Time-to-Event Data: With Applications in R , 2012 .

[12]  A. Whittemore,et al.  Practical Problems With Clinical Guidelines for Breast Cancer Prevention Based on Remaining Lifetime Risk , 2015, Journal of the National Cancer Institute.

[13]  M. Schumacher,et al.  Landmark prediction of nosocomial infection risk to disentangle short- and long-stay patients. , 2017, The Journal of hospital infection.

[14]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[15]  M. Schumacher,et al.  Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores , 2016, Haematologica.

[16]  Martin Schumacher,et al.  Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time , 2015, Clinical Cancer Research.

[17]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[19]  H. Einsele,et al.  A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients , 2017, Haematologica.

[20]  Andre H Crepaldi,et al.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma , 2017, The New England journal of medicine.

[21]  Konstantin Strauch,et al.  Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance , 2012, Breast Cancer Research.

[22]  P. Moreau How I treat myeloma with new agents. , 2017, Blood.

[23]  Eric J Feuer,et al.  Age‐conditional probabilities of developing cancer , 2003, Statistics in medicine.

[24]  H. Putter,et al.  Dynamic Prediction in Clinical Survival Analysis , 2011 .

[25]  R B Geskus,et al.  Dynamic prediction of recurrent events data by landmarking with application to a follow-up study of patients after kidney transplant , 2018, Statistical methods in medical research.

[26]  H. Putter,et al.  Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial. , 2015 .

[27]  Mitchell H. Gail,et al.  Absolute Risk: Methods and Applications in Clinical Management and Public Health , 2018 .

[28]  Hein Putter,et al.  Dynamic prediction of cumulative incidence functions by direct binomial regression. , 2018, Biometrical journal. Biometrische Zeitschrift.

[29]  Jack Cuzick,et al.  Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density , 2018, JAMA oncology.

[30]  Stephan Harbarth,et al.  Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. , 2012, Journal of clinical epidemiology.

[31]  Hein Putter,et al.  Estimation and Prediction in a Multi‐State Model for Breast Cancer , 2006, Biometrical journal. Biometrische Zeitschrift.

[32]  Per Kragh Andersen,et al.  Competing Risks and Time‐Dependent Covariates , 2009, Biometrical journal. Biometrische Zeitschrift.

[33]  G. Lockwood,et al.  Conditional relative survival: a different perspective to measuring cancer outcomes. , 2013, Cancer epidemiology.

[34]  Greg Yothers,et al.  Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Chambers,et al.  When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects , 2011 .

[36]  M. Gail,et al.  Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Thomas A Gerds,et al.  Efron‐Type Measures of Prediction Error for Survival Analysis , 2007, Biometrics.

[38]  James R. Anderson,et al.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Geert Molenberghs,et al.  Dynamic predictions with time‐dependent covariates in survival analysis using joint modeling and landmarking , 2013, Biometrical journal. Biometrische Zeitschrift.

[40]  Katherine S Panageas,et al.  Dynamic prognostication using conditional survival estimates , 2013, Cancer.

[41]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Aeilko H. Zwinderman,et al.  Dynamic prediction of mortality among patients in intensive care using the sequential organ failure assessment (SOFA) score: a joint competing risk survival and longitudinal modeling approach , 2018 .

[43]  J. Harousseau,et al.  How I treat first relapse of myeloma. , 2017, Blood.

[44]  C. Hill,et al.  Prediction of the long‐term survival in breast cancer patients according to the present oncological status , 2002, Statistics in medicine.

[45]  Leonhard Held,et al.  Dynamic clinical prediction models for discrete time‐to‐event data with competing risks—A case study on the OUTCOMEREA database , 2018, Biometrical journal. Biometrische Zeitschrift.

[46]  Tianxi Cai,et al.  The Performance of Risk Prediction Models , 2008, Biometrical journal. Biometrische Zeitschrift.

[47]  E Graf,et al.  Quantifying the Predictive Performance of Prognostic Models for Censored Survival Data with Time‐Dependent Covariates , 2008, Biometrics.